Aveo Hid Kidney Drug's Higher Death Risk, Shareholder Says

Law360, New York (May 10, 2013, 3:06 PM EDT) -- Aveo Pharmaceuticals Inc. was hit with a proposed class action Thursday accusing it of hiding that the U.S. Food and Drug Administration found that its kidney cancer treatment drug Tivozanib increased patients' risk of death more than competitors and that Aveo's trials for the drug were inadequate.

For more than a year, the Massachusetts drugmaker and its top executives led shareholders to believe that Tivozanib, also known as Tivopath, was likely to garner FDA approval, according to a complaint filed in Massachusetts federal court. But on...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

In re Aveo Pharmaceuticals Inc. Securities Litigation


Case Number

1:13-cv-11157

Court

Massachusetts

Nature of Suit

Securities/Commodities

Judge

Denise J. Casper

Date Filed

May 9, 2013

Law Firms

Government Agencies

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.